You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
禮來(LLY.US)將推治療阿茲海默氏症新藥 股價創新高
阿思達克 05-03 23:10
禮來(LLY.US)公布最新臨床試驗數據,指於一項大型臨床試驗中,公司研發的治療認知障礙症其中一種阿茲海默氏症藥物多納單抗(donanemab),可緩減患者清晰思考和執行日常任務能力下降速度三分一以上。 基於臨床結果,禮來計劃於6月底前向美國食品和藥物管理局(FDA)申請批准。根據數據,超過600萬美國人患有阿爾茨海默氏症,預計至2050年將增至近1,300萬。 禮來首席科學和醫學官Daniel Skovronsky指,服用該藥物的試驗者中有47%於一年內的關鍵認知指標沒有下降,而服用安慰劑的參與者中比例則為29%。 禮來周三(3日)股價開市創歷史新高,報415.03美元;最新續升3.8%,報419.47美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account